What determines duration of palliative care before death for patients with advanced disease? A retrospective cohort study of community and hospital palliative care provision in a large UK city

Michael I Bennett, Lucy Ziegler, Matthew Allsop, Sunitha Daniel, Adam Hurlow

ABSTRACT

Objective: For patients with advanced cancer, several randomised controlled trials have shown that access to palliative care at least 6 months before death can improve symptoms, reduce unplanned hospital admissions, minimise aggressive cancer treatments and enable patients to make choices about their end-of-life care, including exercising the choice to die at home. This study determines in a UK population the duration of palliative care before death and explores influencing factors.

Design: This retrospective cohort study analysed referrals to three specialist palliative care services; a hospital-based inpatient palliative care team, and two community-based services (hospices). For each patient referred to any of the above services we identified the date of first referral to that team and calculated the median interval between first referral and death. We also calculated how referral time varied by age, sex, diagnosis and type of palliative care service.

Participants: 4650 patients referred to specialist palliative care services in Leeds UK between April 2012 and March 2014.

Results: Median age of the sample was 75 years. 3903 (84.0%) patients had a diagnosis of cancer. Age, diagnosis and place of referral were significant predictors of duration of palliative care before death. Age was independently associated (J=2 672 078, z=392046.14, r=0.01) with duration of palliative care regardless of diagnosis. Patients over 75 years have 29 fewer days of palliative care than patients under 50. Patients with non-cancer diagnoses have 13 fewer days of palliative care than patients with cancer. Additionally, patients referred to hospital palliative care receive 24.5 fewer days palliative care than those referred to community palliative care services.

Conclusions: The current timing of referral to palliative care may limit the benefits to patients in terms of improvements in end-of-life care, particularly for older patients and patients with conditions other than cancer.

INTRODUCTION

Specialist palliative care services aim to relieve suffering and improve quality of life for people with advanced diseases. For patients with advanced cancer, several randomised controlled trials have shown that early access to palliative care can improve symptoms, reduce unplanned hospital admissions, minimise aggressive cancer treatments and enable patients to make choices about their end-of-life care, including exercising the choice to die at home, which for more than half of patients with cancer is their expressed preference. The trials from which this evidence is derived were conducted in North America and the studies vary widely in their definition of what constitutes palliative care services and who provides them. Common components were an assessment and several follow-up consultations by specialist palliative care teams over a period of 2–3 months. Where reported, patients were
recruited and received these interventions about 6–14 months before their death. Collectively, these data suggest that a dose of three to four palliative care contacts applied about 6 months before death is associated with better end-of-life care.

The accumulating evidence to support early referral is beginning to influence policy within the USA. Following a randomised phase III trial in patients with small cell lung cancer, which demonstrated the benefit of early palliative care involvement in terms of quality of life and survival in 2010, the American Society of Clinical Oncology issued guidance recommending that palliative care should be considered early in the course of illness for any patient with metastatic cancer or high symptom burden. Despite this growing evidence base, within routine clinical practice in the UK palliative care clinicians report that many referrals are made in the last weeks or days of life. This study determines in a UK population the duration of palliative care before death and explores influencing factors.

METHODS
Data and patients
We analysed referrals to three specialist palliative care services in Leeds, UK over a 2-year period (April 2012 to March 2014) relating to 4650 deceased patients. One service was a hospital-based inpatient palliative care team serving an acute hospital and tertiary cancer centre, and two were community-based services (hospices) comprising 18 and 32 inpatient beds, each with its own community home care team. For each palliative care service a data manager employed within each organisation provided anonymised data from their electronic medical record system. For each patient referred to any of the above services, we identified the date of first referral to that team (referrals to community (hospice) palliative care (CPC) can be made by any health professional or the patient; referral to hospital palliative care (HPC) is typically by a health professional within the acute hospital in which the HPC team is based). We calculated the median interval between first referral and death. We also calculated how referral time varied by age, sex, diagnosis and type of palliative care service. The data were systematically checked for outliers, inconsistencies, ambiguous diagnoses and missing data (eg, no date of death). The main variables of interest were age at referral (in years), median time from referral to death (in days), referral location (acute hospital or community hospice), diagnostic grouping (cancer, non-cancer) and subcategories of diagnosis for cancer and non-cancer conditions, as outlined in table 1.

Statistical analysis
All referred adults (n=4650) were included in the descriptive analysis. Median times to death were calculated and the variability was summarised using median absolute deviation (MAD). The median deviation is a measure of scale based on the median of the absolute deviations from the median of the distribution. MAD was used as it is a measure of statistical dispersion that is resistant to outliers. Comparisons between median days from date of referral to death were performed using Mann-Whitney U for cancer versus non-cancer and hospital versus hospice referral. Comparisons for age (<50, 50–74 and 75+ years) were performed using the Kruskal-Wallis test, followed by the Jonckheere-Terpstra test. These analyses were performed using SPSS V22.0. We used median quantile regression to investigate the association between age and sex-standardised median days to death for diagnosis (cancer vs non-cancer) and place of referral (hospital vs hospice). Diagnosis and place of referral were modelled using multivariable quantile regression analyses. This model permits estimation of how the conditional median, or other quantiles (eg, 10th and 90th centile), of a dependent variable y changes with an independent variable x. Diagnosis and place of referral were then included into this model. The model was generated using the qreg command in STATA. Two-tailed p values <0.01 were considered significant.

Patient involvement
Two patients with cancer are co-investigators on the research programme of which the study is part and have informed its design and conduct. They are supporting the active dissemination of the study findings to patients and carers through patient and public involvement networks in a format that can be readily understood by patients, carers and health service commissioners.

RESULTS
Sample characteristics
4650 patients were included in the analysis. 2272 women and 2378 men. The median age of the sample was 75 years; 272 patients were under 50 years, 2014 were 50–74 years of age and 2354 were 75 years or over. In total, 3903 patients had a diagnosis of cancer, 747 had conditions other than cancer. The median duration of palliative care for the whole study population was 34 days (MAD=29 days, indicating that half of the study population had a duration of palliative care that deviated from the median by up to 29 days).

Type of palliative care service
In total, 2746 patients were referred to CPC teams and 1904 to a HPC team. When the services were considered separately (community and hospital), we found the length of palliative care was longer for patients referred to CPC; median 46 days (MAD=38 days) compared with 20 days (MAD=17 days) for referrals to HPC (U=1925555.5, p<0.01, r=−0.22).

Diagnosis and duration of palliative care
The duration of palliative care varied depending on diagnosis. The median duration of palliative care for patients with cancer was 37 days (MAD=31 days).
Patients with conditions other than cancer had significantly shorter duration of palliative care than patients with cancer, overall median 16 days (MAD=14 days) (U=1110511, p<0.01, r=−0.15); longer for CPC (22 days CPC, MAD 19 days) and shorter for HPC (13 days HPC, MAD 11 days).

Within the patient with cancer population, there was variation in duration of palliative care across the different cancer types; patients with breast or prostate cancer had the longest time between referral and death (median days of 43.5 and 48 days, respectively) and patients with haematological or head and neck cancers the shortest (both with a median of 26 days). A Kruskal-Wallis H test showed that there was a statistically significant difference in number of days from referral to death between cancer diagnoses, $\chi^2(14)=58.337$, p<0.001 (figure 1). A breakdown of diagnosis categories for the non-cancer population was only available for the referrals to CPC. These are shown in figure 2.

Patients with dementia or patients who had a stroke had the shortest duration of palliative care before death (median 9 and 5 days, respectively), and patients with motor neuron disease had longest (median 83 days).

**Age and duration of palliative care**

We found a linear relationship between age and duration of palliative care. Patients over 75 years had a median of 29 days (MAD=25 days) palliative care before death, patients between 50 and 74 years, 38 days (MAD=31 days) and those under 50 years had most, 54.5 days (MAD=47 days) ($J=2.672078$, $z=-392046.14$, r=0.01).

**Multivariable quantile regression**

Univariate analysis showed age, diagnosis and place of referral as significant predictors of duration of palliative care before death. The multivariable analysis showed that age is independently associated with duration of palliative care.

| Table 1 Patient characteristics in relation to referral to community and hospital palliative care |
|---------------------------------------------------------------|
|                                                | Community PC n (%) | Hospital PC n (%) | Total n (%) |
| Total                                          | 2746 (59.1)        | 1904 (40.9)       | 4650        |
| Sex                                             |                   |                  |             |
| Men                                             | 1420 (51.7)       | 958 (50.3)       | 2378 (51.1) |
| Women                                           | 1326 (48.3)       | 946 (49.7)       | 2272 (48.9) |
| Diagnosis                                       |                   |                  |             |
| Cancer                                          | 2346 (85.5)       | 1557 (81.8)      | 3903 (83.9) |
| Gynaecological                                  | 120 (5.1)         | 145 (9.3)        | 265 (6.8)  |
| Haematological                                  | 105 (4.5)         | 26 (1.7)         | 131 (3.4)  |
| Kidney                                          | 66 (2.8)          | 46 (3.0)         | 112 (2.9)  |
| Colorectal                                      | 253 (10.8)        | 153 (9.8)        | 406 (10.4) |
| Upper GI                                        | 394 (16.8)        | 221 (14.2)       | 615 (15.8) |
| Lung                                            | 659 (28.1)        | 232 (14.9)       | 891 (22.8) |
| Brain                                           | 79 (3.4)          | 34 (2.2)         | 113 (2.9)  |
| Head and neck                                   | 58 (2.5)          | 65 (4.2)         | 123 (3.2)  |
| Breast                                          | 132 (5.6)         | 172 (11.0)       | 304 (7.8)  |
| Bladder                                         | 76 (3.2)          | 54 (3.5)         | 130 (3.3)  |
| Liver                                           | 45 (1.9)          | 32 (2.1)         | 77 (2.0)   |
| Prostate                                        | 146 (6.2)         | 106 (6.8)        | 252 (6.5)  |
| Kidney                                          | 44 (1.9)          | 85 (5.5)         | 129 (3.3)  |
| Unknown origin                                  | 130 (5.5)         | 51 (3.3)         | 181 (4.6)  |
| Other cancer                                    | 39 (1.7)          | 135 (8.7)        | 174 (4.5)  |
| Non-cancer                                      | 400 (14.6)        | 347 (18.2)       | 747 (16.1) |
| Dementia                                        | 52 (13.0)         | –                | 52 (13.0)  |
| Stroke                                          | 19 (4.8)          | –                | 19 (4.8)   |
| Degenerative disease                            | 8 (2.0)           | –                | 8 (2.0)    |
| Other neurological                              | 27 (6.8)          | –                | 27 (6.8)   |
| Heart failure                                   | 110 (27.5)        | –                | 110 (27.5) |
| Other lung                                      | 96 (24.0)         | –                | 96 (24.0)  |
| Liver failure                                   | 16 (4.0)          | –                | 16 (4.0)   |
| Kidney failure                                  | 36 (9.0)          | –                | 36 (9.0)   |
| Other non-cancer                                | 36 (9.0)          | –                | 36 (9.0)   |
| Non-classified diagnosis                        | –                 | 347 (46.5)       | 347 (46.5) |
| Age, years                                      |                   |                  |             |
| <50 years                                       | 110 (4)           | 172 (9)          | 282 (6)    |
| 50–74 years                                     | 1082 (39.4)       | 932 (48.9)       | 2014 (43.3)|
| 75+ years                                       | 1554 (56.6)       | 800 (42)         | 2354 (50.6)|
palliative care regardless of diagnosis, table 2. Patients over 75 years have 29 fewer days of palliative care than patients under 50. Even when controlling for age and sex, patients with non-cancer diagnoses have 13 fewer days of palliative care than patients with cancer. Additionally, patients referred in hospital receive 24.5 fewer days of palliative care than those referred in the community.

DISCUSSION
This is the first population-level study that quantifies duration of palliative care before death, and identifies significantly different durations of palliative care for older patients and those with non-cancer diagnoses.

Comparison with other studies
In terms of studies exploring duration of palliative care globally, our cohort is second only in terms of population size to a US study exploring duration of palliative care in patients with heart failure. We found the median duration of palliative care in our cohort to be 34 days, significantly shorter than the 6 months the research evidence suggests is optimal. While the duration of palliative care in our cohort appears to be similar to that observed in studies in the USA and Italy, direct comparison is challenging due to the differing characteristics of the palliative services and the components of care they provide. It is however possible to broadly categorise the literature into those studies reporting exposure to hospital-based palliative care services and those reporting community or hospice-based services. Studies from the UK, the USA, Korea and Singapore report the median duration of HPC to range from 14.4 to 57 days and studies reporting CPC from Canada, Italy and Ireland report duration to range from 40 to 70 days. These studies provide useful context to the data reported here (20 days to HPC; 46 days CPC) and show the timing of referral to be consistent with that reported in the international literature.

Having a cancer diagnosis is the primary determinant of access to specialist palliative care. During 2012 to 2013, 88% of palliative care inpatients and 75% of new referrals to hospital support and outpatient services in the UK were for people with a cancer diagnosis, even though cancer accounts for only around 29% of deaths. In our study population, 81% had a diagnosis of cancer which is consistent with the existing evidence that patients with cancer are more likely to access palliative care. Extending palliative care to people with non-cancer diagnoses is a key objective of end-of-life care strategies across the UK; however, access to palliative care for patients with non-cancer is hindered by less predictable disease trajectories and greater difficulty in
identifying a terminal stage. Consistent with this, we found that patients with cancer had \( \sim 13 \) days more palliative care than patients with non-cancer. It is already well evidenced that patients with non-cancer are disadvantaged in terms of access to palliative care but it has not been reported previously that the inequity extends to the duration of care.

We found that increasing age is associated with shorter duration of palliative care. The most recent minimum data set on palliative care activity shows older people are disadvantaged in terms of access; 29% of people accessing specialist palliative care are in the 25–64 age group despite this age group only accounting for 13% of deaths. Whereas people aged 85 or over account for 39% of deaths but represent only 16.4% of referrals to palliative care services. Our study is the first to identify and quantify the shorter duration of palliative care in relation to age and so adds to this evidence base. Older

![Figure 2](https://example.com/image.png)

**Figure 2** Duration of palliative care in relation to non-cancer diagnosis.

| Table 2 | Univariable and multivariable model for duration of palliative care |
|---------|---------------------------------------------------------------|
| Variable | Univariable model | Multivariable model |
| Age | | |
| <50 years | – | – |
| 50–74 years | \(-17 (-27.06, -10.94)\)**+ | \(-20.5 (-29.53, -11.47)\)**+ |
| 75 years and older | \(-26 (-35.13, -16.87)\)**+ | \(-29 (-38.04, -19.96)\)**+ |
| Sex | | |
| Women | – | – |
| Men | \(-5 (-8.95, -1.05)\) | \(-2.5 (-6.66, 1.66)\) |
| Diagnosis | | |
| Cancer | – | – |
| Non-cancer | \(-21 (-26.12, -15.88)\)**+ | \(-13.5 (-19.24, -7.76)\)**+ |
| Place of referral | | |
| Hospice | – | – |
| Hospital | \(-28 (-32.25, -23.75)\)**+ | \(-24.5 (-28.79, -20.21)\)**+ |
people are therefore disadvantaged in access to, and duration of, palliative care before death.

Limitations
This study has limitations. First, it is based in a single UK city and although our findings are consistent with those reported elsewhere, Leeds is particularly well provisioned in terms of palliative care services and our findings may not therefore be representative of practice in other settings with less robust provision. Second, as de-identified data were used, we were unable to identify situations where a referral to HPC and CPC services had occurred. In Leeds, 17% of patients referred to HPC services receive a subsequent CPC referral; therefore, we expect this extent of overlap to be evident in the data reported here.

Third, as retrospective routinely collected clinical data were used, we do not have data on date of diagnosis, which prevents us from relating the duration of palliative care services to the duration of clinical awareness of disease. Late diagnosis may be a key factor in late referral, though the almost universally short duration of palliative care in our cohort suggests that this factor is unlikely to account for the observed referral pattern.

CONCLUSIONS
This study shows that the current timing of referral to palliative care may limit the benefits to patients in terms of improvements in end-of-life care, particularly for older patients and patients with conditions other than cancer. Research is now urgently needed to better understand how the duration of palliative care reported here impacts on the quality of end-of-life care in order to develop and evaluate service-level interventions.

Contributors
MIB, LZ, MA and SD, all contributed to study design. SD led the data analysis and MA led the data validation. MIB, LZ, MA, SD all contributed to the data interpretation and writing of this paper.

Funding
This article presents independent research funded by the National Institute for Health Research (NIHR) (RP-PG-0610-10114). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Competing interests
All authors MIB, LZ, MA, SD have completed the Unified Competing Interest form (http://www.icmje.org/coi_disclosure.pdf available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any commercial entity; no other relationships or activities that could appear to have any conflict of interest with respect to the submitted work.

Ethics approval
NRES Committee Yorkshire and the Humber reference 13/YH/0301.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
No additional data are available.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1. Bakitas M, Lyons KD, Hegel MT, et al. The project ENABLE II randomized controlled trial to improve palliative care for rural patients with advanced cancer: baseline findings, methodological challenges, and solutions. Palliat Support Care 2008;7:75–86.
2. Rabow MW, Dibble SL, Pantilat SZ, et al. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med 2004;164:83–91.
3. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–42.
4. Zimmermann C, Swami N, Krzyzanowska M, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014;383:1721–30.
5. Brumley R, Enguidanos S. Increased satisfaction with home care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc 2007;55:993–1000.
6. El Osta BE, Palmer JL, Paraskevopoulos T, et al. Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med 2008;11:51–7.
7. O’Leary MJ, O’Brien AC, Murphy M, et al. Place of care: from referral to specialist palliative care until death. BMJ Supp Pall Care Published Online First: 8 Dec 2014. doi:10.1136/bmjspcare-2014-000696
8. Mercadante S, Valle A, Saba S, et al. Pattern and characteristics of advanced cancer patients admitted to hospices in Italy. Support Care Cancer 2013;21:935–9.
9. Costantini M, Toscani F, Gallicci M, et al. Terminal cancer patients and timing of referral to palliative care: a multicenter prospective cohort study. J Pain Symptom Manage 1999;18:243–52.
10. Baek YJ, Shin DW, Choi JY, et al. Late referral to palliative care services in Korea. J Pain Symptom Manage 2011;41:692–9.
11. Howell DC. Median absolute deviation, in Wiley statsRef. statistics reference online. John Wiley & Sons, Ltd, 2014.
12. Sawiowsky S, Fahoome G. Kriskal-wallis test: basic, in Wiley statsRef. statistics reference online. John Wiley & Sons, Ltd, 2014.
13. Cheung WY, Schafer K, May CW, et al. Enrollment and events of hospice patients with heart failure vs. cancer. J Pain Symptom Manage 2013;45:552–60.
14. Costantini M, Higginson U, Boni L, et al. Effect of a palliative home care team on hospital admissions among patients with advanced cancer. Palliat Med 2003;17:315–21.
15. Maitoni M, Demri S, Innocenti MP, et al. Description of a home care service for cancer patients through quantitative indexes of evaluation. Tumori 1991;77:453–9.
16. Bennett MJ, Corcoran G. The impact on community palliative care services of a hospital palliative care team. Palliat Med 1994;8:237–44.
17. Dunlop RJ, Davies RJ, Hockley JM. Preferred versus actual place of death: a hospital palliative care support team experience. Palliat Med 1989;3:197–201.
18. Cheng WW, Willey J, Palmer JL, et al. Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med 2005;8:1025–32.
19. Hui D, Kim SH, Kwon JH, et al. Access to palliative care among patients treated at a comprehensive cancer center. Oncologist. 2012;17:1574–80.
20. Lee YJ, Yang JH, Lee JW, et al. Association between the duration of palliative care service and survival in terminal cancer patients. Support Care Cancer 2015;23:1057–62.
21. Poulou VJ, Do YK, Neo PS. Association between referral-to-death interval and location of death of patients referred to a hospital-based specialist palliative care service. J Pain Symptom Manage 2013;46:173–81.
22. McWhinney IR, Bass MJ, Orr V. Factors associated with location of death (home or hospital) of patients referred to a palliative care team. CMAJ 1995;152:361–7.
23. Dixon J, King D, Matosevic T, et al. Equity in the Provision of Palliative Care in the UK: Review of Evidence. 2015. Personal Social Services Research Unit, London School of Economics: London. http://www.pssru.ac.uk/publication-details.php?id=4962
24. Grande GE, Farquhar MC, Barclay SIG, et al. The influence of patient and carer age in access to palliative care services. Age and Ageing 2006;35:267–73.
25. National Council for Palliative Care (NCPC). National survey of patient activity data for specialist palliative care services, minimum data set for 2012 – 2013. 2014. The National Council for Palliative Care: London. http://www.endoflifeicare-intelligence.org.uk/view?rid=803